Patients with erythema migrans and underlying hematological malignancy more often had signs of disseminated Lyme borreliosis and more frequently needed antibiotic retreatment than sex-, age-, and antibiotic treatment-matched immunocompetent persons with erythema migrans. However, the outcome was excellent in both groups.
Patients and controls were evaluated clinically before the start of antibiotic therapy and then at 2 weeks, 2 months, 6 months, and 1 year after the first visit. Serum immunoglobulin (Ig)M and IgG antibodies to Lyme borreliae were determined using an indirect chemiluminescence immunoassay (LIAISON), with antigens OspC and VlsE for detection of IgM antibodies and VlsE for IgG antibodies, or an indirect immunofluorescent test, using as antigen a local isolate of Borrelia afzelii.
In patients who gave consent, a skin biopsy was taken from the border of the EM lesion. Specimens were cultivated in a modified Kelly-Pettenkofer medium and checked for the presence of Borreliae for up to 9 weeks [3] . In patients with positive skin culture results, the procedure was repeated 2-3 months later at the site of the first biopsy. In the majority of patients, a sample of citrated blood was taken for cultivation in the same medium as for skin culture; the procedure was as reported elsewhere [4] .
Isolates were identified to the species/strain level using pulsed-field gel electrophoresis after MluI restriction of genomic DNA or by polymerase chain reaction-based restriction fragment length polymorphism of the intergenic region [3, 5] .
Treatment
At the first visit, patients with HM were treated with doxycycline 100 mg bid for 15 days (14 patients), amoxicillin 500 mg tid for 15 days (13 patients), cefuroxime-axetil 500 mg bid for 15 days (12 patients), azithromycin 500 mg twice on the first day followed by 500 mg od for 4 days (10 patients), or ceftriaxone 2 g od intravenous for 14 days (4 patients with signs indicating disseminated LB).
Complicated Course of LB
Patients with signs of disseminated LB (multiple EM, objective extracutaneous manifestations of LB) and/or those with treatment failure were interpreted as having a complicated course of LB.
Treatment failure was defined as follows: (i) appearance of objective extracutaneous manifestations of LB, (ii) appearance/persistence of subjective symptoms or their increased intensity that could not be attributed to other causes, (iii) persistence of EM (visible EM at visit 2-3 months after the start of antibiotic treatment), or (iv) demonstration of Borreliae by skin culture at the site of previous EM 2-3 months after antibiotic treatment. These patients were retreated with ceftriaxone (i, ii) or an alternative oral antibiotic (iii, iv).
Statistical Methods
Pretreatment characteristics of early LB as well as the course and outcome of the disease after antibiotic therapy in patients with HM were compared with the corresponding findings in a control group of previously healthy persons with EM. The categorical variables were compared using the χ 2 test with Yates continuity correction; numerical variables were compared using the Mann-Whitney test. The percentage or median differences and their 95% confidence intervals (CIs) were reported. CIs for the difference of the medians were based on 10 000 bootstrap samples and on the bias-corrected and accelerated method. The CIs for single proportions were based on the binomial distribution. The statistical language R was used for the analyses [6] .
RESULTS
During the 22-year period analyzed, 53/12 518 (0.4%; 95% CI, .3-.5) patients with EM and underlying HM were diagnosed. Seven of the 53 patients (13.2%) had been reported previously [7] . The group comprised 25 females and 28 males aged 17 to 75 (median 61) years. Solitary EM was diagnosed in 52 (98.1%) patients, and 1 (1.9%) patient presented with multiple skin lesions. Among the 53 patients, 11 had myeloid neoplasms and 42 had lymphoid (B-cell) neoplasms; 16 (30.2%) were receiving antineoplastic treatment (Supplementary Table 1 ).
Characteristics of Early Lyme Borreliosis Before Treatment With Antibiotics
Basic demographic data and pretreatment clinical characteristics of early LB in patients with impaired and normal immunity were analogous for the majority of parameters, including the proportions of patients with serum antibodies to Borreliae, the ratio of patients with positive culture results, and the proportions of the isolated Borreliae according to species (Supplementary Table 2 ). However, at the first visit, signs of early disseminated LB were found in 4/53 (7.6%; 95% CI, 2.1-18.2) patients with HM but in 0/106 immunocompetent patients (0%; 95% CI, 0-3.4; difference in the proportion: 7.6%; 95% CI, 0-16.1; P = .02). All 4 suffered from lymphoid malignancy; 3 had extracutaneous manifestations of LB associated with solitary EM (2 meningoradiculitis, 1 lymphocytic meningitis and peripheral facial palsy), and 1 had multiple EM accompanied by pronounced constitutional symptoms (Table 1) . Patient 1 has already been presented [7] .
Clinical Course and Outcome After Treatment
Duration of EM after the beginning of antibiotic treatment was similar in patients with HM (median, 7; interquartile range, 5-16 days) and their controls (10; interquartile range 7-18 days; P = .24).
The subsequent course and outcome of LB in 4 patients with symptoms and signs of disseminated borrelial infection at presentation and treated with ceftriaxone were favorable. However, 3 (5.7%; 95% CI, 1.2-15.7) other patients with HM (all had underlying lymphoid malignancy) but none in the immunocompetent group (95% CI for the difference: −2 to 13; P = .06) needed additional antibiotic therapy: 1 patient because of development of pronounced subjective symptoms and 1 patient because of persistence of EM; the third patient developed multiple EM (Table 1) . In all 3 patients, the clinical course was uneventful after retreatment with antibiotics.
The course of EM in patients with HM was more often complicated than in patients with normal immunity. Disseminated early LB or treatment failure was diagnosed in 7/53 (13.2%; 95% CI, 5.5-25.3) patients with HM but in 0/106 immunocompetent patients (95% CI, 0-3.4; 95% CI for the difference: 2.7-23.7; P < .0001). The complications were limited to patients with underlying lymphoid neoplasm (complications present in 7/42 patients with lymphoid neoplasm and in 0/11 with underlying myeloid neoplasia; P = .34) and were associated with receiving immunosuppressive drugs. Five of 7 (71.4%, 95% CI, 29.0-96.3) patients with complications vs 11/46 (23.9%; 95% CI, 12.6-38.8) with HM who had an uncomplicated course (P = .03) were receiving therapy against cancer; the corresponding findings for the subgroup of patients with lymphoid malignancy were 5/7 vs 8/35 (23%; 95% CI, 10-40; difference: 48%, 95% CI, 4-93, P = .04). Humoral response to B. burgdorferi sensu lato was established in only 2/7 (28.6%; 95% CI, 3.7-71.0) patients with complications, that is, less often than in patients without complications (25/46; 54.3%; 95% CI, 39-69), though this difference was not statistically significant (P = .39).
At the examination 1 year after the first visit, no objective findings that could have been potentially associated with LB were documented in any patient, including those with and without HM.
DISCUSSION
Results of the present study, based on prospectively collected data at a single European center during a 22-year period, revealed that patients with EM and underlying HM more often had signs of disseminated LB and more frequently needed antibiotic retreatment than sex-, age-, and antibiotic treatmentmatched immunocompetent persons with EM. However, the outcome was excellent in both groups. The results are similar to those suggested for the course and outcome of early LB in patients with miscellaneous causes of immunodeficiency. A MEDLINE literature search revealed individual case reports on patients with LB and various underlying illnesses associated with immunodeficiency, including a few patients with HM [8] [9] [10] [11] [12] and 3 series of patients with EM in immunocompromised hosts [7, 13, 14] . In 2 of the 3 series, patients with HM (7/67 and 9/33, respectively) were also included [7, 13] . However, heterogeneous causes and different levels of immunodeficiency did not enable a reliable assessment of the course and outcome of the LB. Our study showed that the antibiotic treatment approach as used in immunocompetent patients with EM is effective in patients with underlying HM. The results apply to European regions with similar ratios of Borrelia genospecies causing EM, as in Slovenia (80%-90% B. afzelii, 5%-15% B. garinii, <5% other Borrelia species), but may not entirely pertain to North America where LB is caused by B. burgdorferi sensu stricto [15] .
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